Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Welcome and Introduction to Vi3C

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Collyar: What's In It for Patients?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Apr

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Welcome and Introduction to Vi3C

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Collyar: What's In It for Patients?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin

FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation

Prompting Strategies Improve Symptom Monitoring in Childhood Cancer Survivors

Patients With Lung Cancer May Safely Receive Adequate SBRT Dosage in One Treatment